Published in Medical Letter on the CDC and FDA, February 26th, 2006
A number of biotech companies are collaborating with ScinoPharm on new drug development. So far, more than 40 new chemical entity (NCE) projects have been executed, with five of them in the phase III stage of clinical trials. Among the NCE projects, one has been commercialized and one customer listed ScinoPharm as the only supplier in its new drug application (NDA). A second API for NCE projects is expected to be introduced in a year.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.